[en] ¹²⁵I brachytherapy sources are being used for interstitial implants in tumor sites such as the prostate. Recently, the ADVANTAGE^TM125I, Model IAI-125, source became commercially available for interstitial brachytherapy treatment. Dosimetric characteristics (dose rate constant, radial dose function, and anisotropy function) of this source were experimentally and theoretically determined, following the AAPM Task Group 43 recommendations. Derivation of the dose rate constant was based on recent NIST WAFAC calibration performed in accordance with their 1999 standard. Measurements were performed in Solid Water^TM phantom using LiF thermoluminescent dosimeters. The theoretical calculations were performed in both Solid Water^TM and water using the PTRAN Monte Carlo code. The results indicated that a dose rate constant of the new source in water was 0.98±0.03 cGy h^-1 U^-1. The radial dose function of the new source was measured in Solid Water^TM and calculated both in water and Solid Water^TM at distances up to 10.0 cm. The anisotropy function, F(r,θ), of the new source was measured and calculated in Solid Water^TM at distances of 2 cm, 3 cm, 5 cm, and 7 cm and also was calculated in water at distances ranging from 1 cm to 7 cm from the source. From the anisotropy function, the anisotropy factors and anisotropy constant were derived. The anisotropy constant of the ADVANTAGE^TM125I source in water was found to be 0.97±0.03. The dosimetric characteristics of this new source compared favorably with those from the Amersham Health Model 6711 source. Complete dosimetric parameters of the new source are presented in this paper